Early results in the novel use of contrast-enhanced susceptibility-weighted imaging in the assessment of response and progression in desmoid fibromatosis: A pilot study in a specialized cancer institution

Tumor discovery Pub Date : 2023-11-06 DOI:10.36922/td.1414
Raul F. Valenzuela, Elvis Duran Sierra, Mathew A. Canjirathinkal, Colleen M. Costelloe, John E. Madewell, William A. Murphy Jr., Behrang Amini
{"title":"Early results in the novel use of contrast-enhanced susceptibility-weighted imaging in the assessment of response and progression in desmoid fibromatosis: A pilot study in a specialized cancer institution","authors":"Raul F. Valenzuela, Elvis Duran Sierra, Mathew A. Canjirathinkal, Colleen M. Costelloe, John E. Madewell, William A. Murphy Jr., Behrang Amini","doi":"10.36922/td.1414","DOIUrl":null,"url":null,"abstract":"Routine radiologic reporting (RRR) often considers progressive desmoid tumors to have a higher proportion of T2-hyperintense and T1-shortened-enhancing components, while responsive or mature collagenized tumors demonstrate a higher proportion of T2-hypointense-non-enhancing components. We aim to determine the utility of the novel use of contrast-enhanced susceptibility-weighted imaging (CE-SWI) in Desmoid-Tumor treatment response assessment, distinguishing between the T1-shortening-enhancing/T2-hyperintense immature components from the T2-hypointense mature collagenized components. This pilot study included 10 single-lesion extremity desmoid fibromatosis patients undergoing standard-of-care magnetic resonance imaging, including CE-SWI. Three-dimensional (3D) tumor segmentation was performed using MIM software in 48 volumes of interest. Maximum diameter, volume, and modified Choi (mChoi) measurements were computed from CE-SWI and T2-weighted image (T2-WI). Five first-order radiomic features, including mean, skewness, kurtosis, and 10th and 90th percentiles, were calculated using in-house developed software (CARPI-AF). (i) RECIST Progression: We observed two cases of progression according to the T2-WI-based Response Evaluation Criteria in Solid Tumors standard (RECIST). Interestingly, CE-SWI-based-volume and CE-SWI-based-mChoi predicted the same assessment 4.5 months earlier than T2-WI-based-RECIST. RRR assessed both cases as progression; (ii) RECIST Stability: Out of the eight patients classified as having stable disease by T2-WI-based-RECIST, four discrepant progressions were determined: three patients showed an increase greater than 25% of T2-WI-based-volume, and two patients showed an increase greater than 25% of CE-SWI-based-volume. Moreover, from the RECIST stable group, four discrepant-positive responses were predicted by CE-SWI-based-mChoi (three patients) and T2-WI-based-mChoi (four patients). RRR only assessed one patient as having progressive disease; (iii) First-Order Radiomics: CE-SWI detected 23% more 90th-percentile voxels than T2-WI, while T2-WI demonstrated 8.5% more 10th-percentile voxels than CE-SWI. Notably, expected first-order response/progression-related changes in 10th-percentile, 90th-percentile, mean, and skewness were present in 90% of cases. In conclusion, CE-SWI-based-volume and CE-SWI-based-mChoi measurements could improve the prediction of response/progression in desmoid tumors, enhancing the ability in discriminating between T2*- hypointense-collagenized-mature and T1-shortened-enhancing immature components, respectively, in predominant mature responsive and immature progressive tumors, respectively. RRR is relatively insensitive to volumetric tumor changes before RECIST progression and tends to be better tuned with T2* signal and enhancement changes.","PeriodicalId":94260,"journal":{"name":"Tumor discovery","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumor discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36922/td.1414","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Routine radiologic reporting (RRR) often considers progressive desmoid tumors to have a higher proportion of T2-hyperintense and T1-shortened-enhancing components, while responsive or mature collagenized tumors demonstrate a higher proportion of T2-hypointense-non-enhancing components. We aim to determine the utility of the novel use of contrast-enhanced susceptibility-weighted imaging (CE-SWI) in Desmoid-Tumor treatment response assessment, distinguishing between the T1-shortening-enhancing/T2-hyperintense immature components from the T2-hypointense mature collagenized components. This pilot study included 10 single-lesion extremity desmoid fibromatosis patients undergoing standard-of-care magnetic resonance imaging, including CE-SWI. Three-dimensional (3D) tumor segmentation was performed using MIM software in 48 volumes of interest. Maximum diameter, volume, and modified Choi (mChoi) measurements were computed from CE-SWI and T2-weighted image (T2-WI). Five first-order radiomic features, including mean, skewness, kurtosis, and 10th and 90th percentiles, were calculated using in-house developed software (CARPI-AF). (i) RECIST Progression: We observed two cases of progression according to the T2-WI-based Response Evaluation Criteria in Solid Tumors standard (RECIST). Interestingly, CE-SWI-based-volume and CE-SWI-based-mChoi predicted the same assessment 4.5 months earlier than T2-WI-based-RECIST. RRR assessed both cases as progression; (ii) RECIST Stability: Out of the eight patients classified as having stable disease by T2-WI-based-RECIST, four discrepant progressions were determined: three patients showed an increase greater than 25% of T2-WI-based-volume, and two patients showed an increase greater than 25% of CE-SWI-based-volume. Moreover, from the RECIST stable group, four discrepant-positive responses were predicted by CE-SWI-based-mChoi (three patients) and T2-WI-based-mChoi (four patients). RRR only assessed one patient as having progressive disease; (iii) First-Order Radiomics: CE-SWI detected 23% more 90th-percentile voxels than T2-WI, while T2-WI demonstrated 8.5% more 10th-percentile voxels than CE-SWI. Notably, expected first-order response/progression-related changes in 10th-percentile, 90th-percentile, mean, and skewness were present in 90% of cases. In conclusion, CE-SWI-based-volume and CE-SWI-based-mChoi measurements could improve the prediction of response/progression in desmoid tumors, enhancing the ability in discriminating between T2*- hypointense-collagenized-mature and T1-shortened-enhancing immature components, respectively, in predominant mature responsive and immature progressive tumors, respectively. RRR is relatively insensitive to volumetric tumor changes before RECIST progression and tends to be better tuned with T2* signal and enhancement changes.
对比增强敏感性加权成像在评估硬纤维瘤病的反应和进展方面的新应用的早期结果:一项专门癌症机构的初步研究
常规放射学报告(RRR)通常认为进展性硬纤维瘤具有较高比例的t2高信号和t1缩短增强成分,而反应性或成熟的胶原瘤具有较高比例的t2低信号非增强成分。我们的目的是确定对比增强敏感性加权成像(CE-SWI)在硬纤维瘤治疗反应评估中的新应用,区分t1缩短增强/ t2高强度未成熟成分和t2低强度成熟胶原成分。本初步研究纳入了10例接受标准磁共振成像(包括CE-SWI)的单病变肢体硬纤维瘤病患者。使用MIM软件对48个感兴趣的体积进行三维(3D)肿瘤分割。根据CE-SWI和t2加权图像(T2-WI)计算最大直径、体积和改良Choi (mChoi)测量值。使用内部开发的软件(CARPI-AF)计算5个一阶放射学特征,包括平均值、偏度、峰度以及第10和第90百分位。(i) RECIST进展:我们观察到2例进展,根据实体瘤中基于t2 - wi的反应评估标准(RECIST)。有趣的是,基于ce - wi的volume和基于ce - wi的mchoi预测相同的评估比基于t2 - wi的recist早4.5个月。RRR将这两例病例评估为进展;(ii) RECIST稳定性:在8例经t2 - wi -based RECIST分类为病情稳定的患者中,确定了4例差异进展:3例患者的t2 - wi -based容积增加大于25%,2例患者的ce - wi -based容积增加大于25%。此外,在RECIST稳定组中,基于ce - wi的mchoi(3例)和基于t2 - wi的mchoi(4例)预测了4例差异阳性反应。RRR仅评估一名患者为进行性疾病;(iii)一阶放射组学:CE-SWI检测到的第90百分位体素比T2-WI多23%,而T2-WI检测到的第10百分位体素比CE-SWI多8.5%。值得注意的是,在90%的病例中,预期的第10百分位、第90百分位、平均值和偏度的一阶反应/进展相关变化存在。综上所述,基于ce - swi的体积和基于ce - swi的mchoi测量可以提高对硬纤维瘤反应/进展的预测,增强了在主要的成熟反应性肿瘤和未成熟进展性肿瘤中分别区分T2*-低强度胶原-成熟和t1缩短-增强未成熟成分的能力。在RECIST进展前,RRR对肿瘤体积变化相对不敏感,并倾向于更好地调节T2*信号和增强变化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信